Abstract
Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p
| Original language | Italian |
|---|---|
| Pages (from-to) | 24-27 |
| Number of pages | 4 |
| Journal | Recenti Progressi in Medicina |
| Volume | 97 |
| Issue number | 1 |
| Publication status | Published - Jan 2006 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi. / Benucci, Maurizio; Dolenti, Stefano; Saviola, Gianantonio; Manfredi, Mariangela.
In: Recenti Progressi in Medicina, Vol. 97, No. 1, 01.2006, p. 24-27.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi
AU - Benucci, Maurizio
AU - Dolenti, Stefano
AU - Saviola, Gianantonio
AU - Manfredi, Mariangela
PY - 2006/1
Y1 - 2006/1
N2 - Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p
AB - Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p
KW - Glucocorticoids induced osteoporosis
KW - Neridronate
KW - Rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=33645319765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645319765&partnerID=8YFLogxK
M3 - Articolo
C2 - 16535926
AN - SCOPUS:33645319765
VL - 97
SP - 24
EP - 27
JO - Recenti Progressi in Medicina
JF - Recenti Progressi in Medicina
SN - 0034-1193
IS - 1
ER -